NewAmsterdam Pharma Announces Conference Participation
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is gearing up for an exciting lineup of presentations at key medical and investor conferences. As a leader in developing innovative oral therapies for cardiovascular disease, NewAmsterdam is set to share groundbreaking research findings and engage with stakeholders in the healthcare community.
Key Presentations at the 2024 AHA Scientific Sessions
At the upcoming 2024 American Heart Association (AHA) Scientific Sessions, NewAmsterdam will present significant safety and efficacy data from its pivotal Phase 3 BROOKLYN study. This research focuses on obicetrapib, a promising treatment for patients suffering from Heterozygous Familial Hypercholesterolemia, a genetic condition characterized by high levels of low-density lipoprotein cholesterol (LDL-C).
Details of the Presentation
Scheduled for November 18, 2024, the presentation will discuss the following aspects:
- Title: Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia (BROOKLYN)
- Session Title: Late-Breaking Science 8: New Targets and New Treatments: Advances in Lipid Therapeutics
- Presenter: Stephen Nicholls, M.B.B.S., Ph.D., a renowned expert from Monash University
Participation in the Jefferies London Healthcare Conference
NewAmsterdam will also take part in the Jefferies London Healthcare Conference from November 19-21, where management will discuss the company's advancements and future directions in cardiovascular therapies.
Conference Highlights
The fireside chat, happening on November 21, 2024, will feature:
- Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam
- John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer
- Ian Somaiya, Chief Financial Officer
Innovative Development of Obicetrapib
Obicetrapib stands out as a unique oral, low-dose CETP inhibitor designed to enhance the treatment landscape for patients facing cardiovascular risks. Through a robust series of clinical trials, including Phase 2 studies like ROSE2, TULIP, ROSE, and OCEAN, NewAmsterdam has demonstrated not only significant LDL-lowering effects but also a safety profile resembling that of a placebo.
Continued Clinical Trials and Research
The company is actively engaging in additional trials to validate obicetrapib's effectiveness:
- BROADWAY Trial: Investigates obicetrapib as an adjunct to maximal lipid-lowering therapies.
- TANDEM Trial: Studies the combination of obicetrapib and ezetimibe as a fixed-dose treatment.
- PREVAIL Trial: Focused on assessing cardiovascular outcomes, enrolling more than 9,500 participants.
Commitment to Patients with Metabolic Diseases
NewAmsterdam's mission is to tackle the unmet needs for safe and effective therapies in the management of metabolic diseases. The company aims to bring its oral, once-daily CETP inhibitor to various markets, catering specifically to patients who have been underserved by existing treatment options.
Partnering for Success
The commercialization rights for obicetrapib within Europe have been granted to the Menarini Group, an experienced international pharmaceutical organization. This strategic partnership underscores NewAmsterdam's commitment to ensuring that its innovative therapies reach those who need them most.
Stay in Touch with NewAmsterdam
As NewAmsterdam prepares for these significant upcoming events, stakeholders and interested parties should feel free to reach out for more information or engage with the company through the following contacts:
Company Contact
Matthew Philippe
P: 1-917-882-7512
Email: matthew.philippe@newamsterdampharma.com
Media Contact
Spectrum Science on behalf of NewAmsterdam
Bryan Blatstein
P: 1-917-714-2609
Email: bblatstein@spectrumscience.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
Email: austin.murtagh@precisionaq.com
Frequently Asked Questions
What is the primary focus of NewAmsterdam Pharma's research?
NewAmsterdam Pharma focuses on developing novel oral therapies aimed at lowering LDL cholesterol levels in patients at risk of cardiovascular disease.
When will the AHA presentation on obicetrapib occur?
The presentation is scheduled for November 18, 2024, during the AHA Scientific Sessions.
Who will present at the Jefferies London Healthcare Conference?
Key presentations will be made by Chief Executive Officer Michael Davidson, Chief Scientific Officer John Kastelein, and Chief Financial Officer Ian Somaiya.
What is the significance of obicetrapib?
Obicetrapib is being developed as a lower-risk treatment option with a promising efficacy profile for patients with familial hypercholesterolemia.
How does NewAmsterdam Pharma engage with investors?
NewAmsterdam provides regular updates through conferences, investor relations webcasts, and communications from their investor contact.
